Navigation Links
Arpida-Supported CME Symposium Available Online
Date:12/14/2007

REINACH, Switzerland, December 14 /PRNewswire-FirstCall/ -- As reported in September, Arpida Ltd. (SWX: ARPN) had a significant presence at this year's Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). A webcast of a CME accredited symposium at ICAAC, that was supported through an educational grant by Arpida, is available online at http://www.IDCME.org.

The symposium is entitled "Treatment of Methicillin-resistant Staphylococcus aureus and Other Resistant Infections: An Expert Debate". In it distinguished speakers such as John G. Bartlett, MD, Louis B. Rice, MD, Dennis L. Stevens, PhD, MD, Gregory J. Moran, MD, FACEP and Robert C. Moellering, Jr., MD, MACP discuss the latest trends in their field. Topics include the increasing incidence of MRSA infections both in the healthcare setting and in the community, existing and emerging treatment options, as well as the changing landscape of bacterial resistance.

ICAAC is recognised as a premier global meeting for clinicians, researchers and scientists in the field of infectious diseases. In addition to the support of the CME symposium Arpida's participation comprised an exhibition booth which generated significant interest among the conference attendees as well as presentation of a total of 32 posters: 19 on the late-stage investigational antibiotic iclaprim and a total of 13 on AR-709 and AR-2474.

About the CME symposium

This CME (Continuing Medical Education) symposium should be seen as an educational activity, aimed primarily at healthcare professionals. Arpida Ltd. supported this educational activity through an unrestricted educational grant. The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Arpida Ltd., or the organisers. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial close to NDA-filing and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent, pathogen-focused, late-stage antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In March 2007, Arpida completed patient enrolment in the second pivotal Phase III trial in complicated skin and skin structure infections. The top-line data of the second trial were reported in July 2007.

In December 2007, Arpida announced the enrolment and dosing of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

An oral formulation of iclaprim has successfully completed four Phase I trials. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is about to enter Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Arpida contacts:

Dr Khalid Islam,

President and CEO

Tel: +41-61-417-96-60

Harry Welten, MBA,

CFO and Senior Vice President,

Tel: +41-61-417-96-65

Paul Verbraeken,

Head of Corporate Communications,

Tel: +41-61-417-96-83


'/>"/>
SOURCE Arpida
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
2. Stevens to host Nanoscience/Nanotechnology & Corrosion symposium, Nov. 13
3. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
4. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
5. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
6. Luminex Corporation Hosts the Fifth Annual Planet xMAP Europe 2007 Symposium
7. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
8. Leading Pharmaceutical Communication Executives Gather for the 1st Annual Pharmaceutical Public Relations Symposium
9. The Parkinsons Disease Foundation Commemorates its 50th Anniversary with Special Scientific Symposium on Parkinsons Disease
10. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
11. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017 NetworkNewsWire Editorial Coverage  ... Cancer ... significant strain on health care systems, in terms of costs ... so too does the development of innovative and efficient therapies ... Among the many types of cancer treatments, a growing number ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... announced the hire of Dr. Sigmund “Sig” Floyd as Vice President ? Global ... and joint development activities. , “Dr. Floyd’s career has spanned 30 years in ...
(Date:3/22/2017)... MONICA, Calif. , March 22, 2017 /PRNewswire/ ... are proud to announce their extended partnership and ... will be headlined by the 21 st ... BIOMEDevice Boston, taking place May 3-4, 2017. ... Advanced Medical Technology Association (ADVAMED) President and CEO, ...
(Date:3/22/2017)... ALBANY, New York , March 22, 2017 /PRNewswire/ ... market is largely fragmented, states a research report by ... Sanofi S.A., Pfizer Inc., Amgen Inc., and AbbVie Inc., ... market in 2015. The prominent players in this market ... to expand their product portfolio, which is likely to ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:2/28/2017)... 2017 News solutions for biometrics, bag drop ... ... 14 to 16 March, Materna will present its complete end-to-end ... travel is a real benefit for passengers. To accelerate the ... passenger touch point solutions to take passengers through the complete ...
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
Breaking Biology News(10 mins):